Comparatively, women with triple-negative breast cancer lost more weight compared to women with ER/PR+, HER2− tumors at 1 year (−0.60 kg versus −0.01 kg, p < 0.001) and 5 years post-diagnosis (−1.63 kg vs. −0.90 kg, p < 0.001). This evidence concerns the gene PGR and triple-negative breast carcinoma.